331 related articles for article (PubMed ID: 16385545)
21. COX-2-specific inhibitors: prescribing patterns in a large managed care health system and strategies to minimize costs.
Weideman RA; Kelly KC; Kelley CL; Cryer B
Am J Manag Care; 2002 Oct; 8(10):869-77. PubMed ID: 12395955
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies.
Birbara C; Ruoff G; Sheldon E; Valenzuela C; Rodgers A; Petruschke RA; Chang DJ; Tershakovec AM
Curr Med Res Opin; 2006 Jan; 22(1):199-210. PubMed ID: 16393445
[TBL] [Abstract][Full Text] [Related]
23. Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice.
Wolfe F; Michaud K; Burke TA; Zhao SZ
J Rheumatol; 2004 Feb; 31(2):355-8. PubMed ID: 14760808
[TBL] [Abstract][Full Text] [Related]
24. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism.
Patel MI; Subbaramaiah K; Du B; Chang M; Yang P; Newman RA; Cordon-Cardo C; Thaler HT; Dannenberg AJ
Clin Cancer Res; 2005 Mar; 11(5):1999-2007. PubMed ID: 15756026
[TBL] [Abstract][Full Text] [Related]
25. Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2.
Fries S; Grosser T; Price TS; Lawson JA; Kapoor S; DeMarco S; Pletcher MT; Wiltshire T; FitzGerald GA
Gastroenterology; 2006 Jan; 130(1):55-64. PubMed ID: 16401468
[TBL] [Abstract][Full Text] [Related]
26. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
Schneeweiss S; Solomon DH; Wang PS; Rassen J; Brookhart MA
Arthritis Rheum; 2006 Nov; 54(11):3390-8. PubMed ID: 17075817
[TBL] [Abstract][Full Text] [Related]
27. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
Rahme E; Nedjar H
Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
[TBL] [Abstract][Full Text] [Related]
28. Persistency of use of COX-2-specific inhibitors and non-specific non-steroidal anti-inflammatory drugs (NSAIDs) in Quebec.
Moride Y; Ducruet T; Rochon S; Lavoie F
Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii17-22. PubMed ID: 14585914
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and tolerability of celecoxib compared with diclofenac slow release in the treatment of acute ankle sprain in an Asian population.
Nadarajah A; Abrahan L; Lau FL; Hwang LJ; Fakir-Bolte C
Singapore Med J; 2006 Jun; 47(6):534-42. PubMed ID: 16752024
[TBL] [Abstract][Full Text] [Related]
30. Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans.
Werner U; Werner D; Rau T; Fromm MF; Hinz B; Brune K
Clin Pharmacol Ther; 2003 Aug; 74(2):130-7. PubMed ID: 12891223
[TBL] [Abstract][Full Text] [Related]
31. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas.
Solomon SD; Pfeffer MA; McMurray JJ; Fowler R; Finn P; Levin B; Eagle C; Hawk E; Lechuga M; Zauber AG; Bertagnolli MM; Arber N; Wittes J;
Circulation; 2006 Sep; 114(10):1028-35. PubMed ID: 16943394
[TBL] [Abstract][Full Text] [Related]
32. Effect of nonsteroidal anti-inflammatory drugs with varying extent of COX-2-COX-1 selectivity on urinary sodium and potassium excretion in the rat.
Harirforoosh S; Jamali F
Can J Physiol Pharmacol; 2005 Jan; 83(1):85-90. PubMed ID: 15759054
[TBL] [Abstract][Full Text] [Related]
33. Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells.
Niederberger E; Manderscheid C; Grösch S; Schmidt H; Ehnert C; Geisslinger G
Biochem Pharmacol; 2004 Jul; 68(2):341-50. PubMed ID: 15194006
[TBL] [Abstract][Full Text] [Related]
34. Persistence with COX-2 inhibitors in managed care: an analysis of claims data.
Harley C; Wagner S
Manag Care Interface; 2003 Oct; 16(10):38-45. PubMed ID: 14606259
[TBL] [Abstract][Full Text] [Related]
35. Withdrawal of COX-2 selective inhibitors rofecoxib and valdecoxib: impact on NSAID and gastroprotective drug prescribing and utilization.
Sun SX; Lee KY; Bertram CT; Goldstein JL
Curr Med Res Opin; 2007 Aug; 23(8):1859-66. PubMed ID: 17605893
[TBL] [Abstract][Full Text] [Related]
36. Therapy switching and associated costs in elderly patients receiving COX-2 selective inhibitors or non-selective non-steroidal anti-inflammatory drugs in Quebec, Canada.
Rahme E; Toubouti Y; Hunsche E
Rheumatology (Oxford); 2006 Jul; 45(7):903-10. PubMed ID: 16461440
[TBL] [Abstract][Full Text] [Related]
37. Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease.
Renda G; Tacconelli S; Capone ML; Sacchetta D; Santarelli F; Sciulli MG; Zimarino M; Grana M; D'Amelio E; Zurro M; Price TS; Patrono C; De Caterina R; Patrignani P
Clin Pharmacol Ther; 2006 Sep; 80(3):264-74. PubMed ID: 16952493
[TBL] [Abstract][Full Text] [Related]
38. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition.
Weber A; Casini A; Heine A; Kuhn D; Supuran CT; Scozzafava A; Klebe G
J Med Chem; 2004 Jan; 47(3):550-7. PubMed ID: 14736236
[TBL] [Abstract][Full Text] [Related]
39. Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study.
Sieper J; Klopsch T; Richter M; Kapelle A; Rudwaleit M; Schwank S; Regourd E; May M
Ann Rheum Dis; 2008 Mar; 67(3):323-9. PubMed ID: 17616556
[TBL] [Abstract][Full Text] [Related]
40. Risk of congestive heart failure with nonsteroidal antiinflammatory drugs and selective Cyclooxygenase 2 inhibitors: a class effect?
Hudson M; Rahme E; Richard H; Pilote L
Arthritis Rheum; 2007 Apr; 57(3):516-23. PubMed ID: 17394181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
